Metagenomi plunges 67% on earnings miss, collaboration revenue collapse
Gene editing biotech reports $87.9M net loss as revenue tumbles 51.8%, but $160.8M cash provides runway
Metagenomi shares tumbled in Thursday trading after the gene editing biotechnology company reported full-year 2025 financial results that fell dramatically short of analyst expectations, with collaboration revenue collapsing by more than half amid a widening net loss.
The Emeryville, California-based company reported an adjusted loss per share of $2.36 for fiscal 2025, missing analyst estimates by 342% compared to the expected loss of $0.53, according to the company's earnings announcement. The significant miss came as collaboration revenue plunged 51.8% year-over-year to $25.2 million, down from $52.3 million in 2024.
Metagenomi's net loss widened to $87.9 million for fiscal 2025, compared to a loss of $78.1 million in the prior year, reflecting the challenges facing the biotechnology company as it advances its pipeline of gene editing therapies. The revenue decline highlights the volatility inherent in biotech collaboration models, which can swing dramatically based on partner priorities and research milestones.
Despite the disappointing financial results, the company maintained a strong balance sheet with $160.8 million in cash and cash equivalents as of September 30, 2025. This capital position provides a runway through the fourth quarter of 2027, giving management time to advance key programs without immediate funding concerns, according to the earnings release.
On the clinical development front, Metagenomi highlighted progress on its MGX-001 hemophilia program, which remains on track for an Investigational New Drug (IND) application submission in the fourth quarter of 2026. The program represents the company's most advanced therapeutic candidate and will be a critical catalyst for shareholder value in the coming year.
The earnings report underscores the execution challenges facing early-stage biotechnology companies, particularly those dependent on collaboration revenue from larger pharmaceutical partners. Metagenomi, which develops therapeutics using metagenomics-derived genome editing tools, must demonstrate both clinical progress and a sustainable path to commercialization to regain investor confidence.
Analyst consensus data indicates a target price of $9.33 for MGX shares, with ratings including four buy recommendations and one hold. This bullish analyst sentiment suggests that the market may be overreacting to the near-term financial weakness, focusing instead on the long-term potential of the company's gene editing platform.
Metagenomi's low beta of 0.47 indicates the stock has historically been less volatile than the broader market, though today's dramatic sell-off represents a significant departure from that pattern. The company's market capitalization stands at approximately $56.7 million, with shares currently trading near their 52-week low of $1.23 and well off the yearly high of $3.95.
Looking ahead, investors will be closely watching the IND submission for MGX-001 in late 2026, which could serve as a significant value inflection point. The company's ability to secure additional collaboration partnerships and advance other pipeline candidates will also be critical factors in determining whether MGX shares can recover from today's steep decline.